Pharmacokinetic evaluation of fosaprepitant dimeglumine.

ABSTRACT:

Importance of the field

Chemotherapy induced nausea and vomiting (CINV) is a common complication in the treatment of patients with cancer. The introduction of the first in class neurokinin-1 receptor antagonist aprepitant provided additive control on CINV in combination to existing antiemetics. Due to formulation issues, aprepitant is only available for oral administration. Fosaprepitant, a prodrug of aprepitant, was introduced to the market in 2008 as an intravenous bioequivalent to aprepitant.

Areas covered in this review

This review examines the chemical development of fosaprepitant, its pharmacokinetic properties, approved uses and potential applications.

What the reader will gain

The reader will get up-to-date information on the pharmacology and clinical uses of

SUBMITTER: Colon-Gonzalez F 

PROVIDER: S-EPMC3155701 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature